Site icon Diseases Treatments Dictionary

Bleeding Disorder – Mechanism, Complications, and Treatment.

Definition

Bleeding disorder is a group of conditions that result when the blood cannot clot properly. In normal clotting, platelets, a type of blood cell, stick together and form a plug at the site of an injured blood vessel. Proteins in the blood called clotting factors then interact to form a fibrin clot, essentially a gel plug, which holds the platelets in place and allows healing to occur at the site of the injury while preventing blood from escaping the blood vessel.

 

Bleeding Disorder Categories

There are several types of bleeding disorders, many of which are named for the specific clotting factor that is deficient.

Hemophilia is the best-known inherited bleeding disorder.  There are two main types:

  1. Hemophilia A, also called Factor VIII hemophilia, is caused by a lack of the blood clotting factor VIII.
  2. Hemophilia B, also called Factor IX hemophilia or Chistmas disease, is caused by a lack of the blood clotting factor IX.

Coagulation Cascade

The process by which blood clots are formed involves a complex set of reactions collectively called the coagulation cascade This cascade is stimulated by clotting factors released from damaged cells (extrinsic pathway) and platelets (intrinsic pathway) The coagulation cascade involves many intermediary steps, however the principal events are as follows:

Epidemiology and prevalence

Hemophilia A is the most common X-linked genetic disease and the second most common factor deficiency after von Willebrand disease (vWD). The worldwide incidence of hemophilia A is approximately 1 case per 5000 male individuals, with approximately one third of affected individuals not having a family history.

The prevalence of hemophilia A is 20.6 cases per 100,000 male individuals, with 60% of those having severe disease. Hemophilia B is estimated to be approximately 1 case per 25,000-30,000 male births. The prevalence of hemophilia B is 5.3 cases per 100,000 male individuals, with 44% of those having severe disease. Hemophilia B is much less common than hemophilia A. Of all hemophilia cases, 80-85% are hemophilia A, 14% are hemophilia B, and the remainder are various other clotting abnormalities

History

1828 – Term “haemorrhaphilia” first used. Later shortened to “haemophilia.”

1926 – Erik von Willebrand identifies a bleeding disorder, later called von Willebrand disease (VWD)

1940s – Whole blood transfusions given at hospital

1948 – National Hemophilia Foundation (NHF) opens as The Hemophilia Foundation, Inc.

1952 – Researchers describe what is now called factor IX clotting protein

1954 – NHF establishes a Medical Advisory Council, later called Medical and Scientific Advisory Council (MASAC)

1955 – First infusions of factor VIII in plasma form

1957 – Researchers in Sweden identify von Willebrand factor as the cause of VWD

1958 – First use of prophylaxis for hemophilia A

1964 – Dr. Judith Graham Pool discovers cryoprecipitate

1968 – First FVIII concentrate available

1970s – Primary prophylaxis therapy experiments begin

1970s – Freeze-dried plasma-derived factor concentrates available

1977 – Desmopressin identified to treat mild hemophilia and von Willebrand disease

1980s – Factor VIII, FIX and von Willebrand factor genes cloned

1982 – CDC reports first AIDS cases among people with hemophilia

1985 – First inactivated factor concentrates available

1992 – FDA approves first recombinant FVIII products

1995 – Prophylaxis becomes standard of treatment in US

1997 – FDA approves first recombinant FIX products

1998 – First human gene therapy trials begin

2000s – FDA approves first recombinant factor products made without human or animal plasma derivatives

2009 – FDA approves RiaSTAP to treat factor I deficiency

2011 – FDA approves Corifact to treat factor XIII deficiency

2013 – Gene therapy trials underway at three sites in the US

Causes

Normal blood clotting involves as many as 20 different plasma proteins, which are known as blood clotting or coagulation factors. These factors act together with other chemicals to form a substance called fibrin that stops bleeding. Problems can occur when certain coagulation factors are low or missing. Bleeding problems can range from mild to severe.

Some bleeding disorders are present at birth and are passed through families (inherited). Others develop from:

Aceclofenac Fluoxetine* Naproxen
Acenocoumarol Fluvoxamine* Paroxetine*
Acetylsalicylic acid (Aspirin) Ibuprofen Phenprocoumon
Citalopram* Indomethacin Piroxicam
Clopidogrel Ketoprofen Sertraline*
Dexibrufen Ketorolac Sulindac
Diclofenac Lornoxicam Tenoxicam
Dicoumarol Meloxicam Ticlopidine
Escitalopram Nabumetone Warfarin

Herbal drugs (phytomedicines) that can cause bleeding includes

Manifestations

Symptoms of bleeding disorders may include:

Complications associated with bleeding disorder

Joint Damage: This occurs when there is repeated bleeding into the joints. Joint bleeds cause pain and discomfort that can lead to chronic swelling and deformity.

Inhibitors: Inhibitors are antibodies that the body develops because it sees the infused factor as a foreign substance that needs to be destroyed. Antibodies are proteins that eat up the activated factor before it has time to stop the bleeding.

Viral Infection: there is always a remote risk of a new virus being introduced into the blood supply and therefore, into the plasma derived factor concentrates.

Emotional and Psychological: Feelings are normal and everyone experiences positive and negative feelings at different times in their lives. Being diagnosed with a chronic condition or learning that your child has a chronic condition may make a person feel stressed, sad, and sometimes depressed.

Exams and Tests

Complete blood count (CBC)

A complete blood count (CBC) is a blood test used to evaluate your overall health and detect a wide range of disorders, including anemia, infection and leukemia.

Bleeding time

Bleeding time is a crude test of hemostasis (the arrest or stopping of bleeding). It indicates how well platelets interact with blood vessel walls to form blood clots.

Partial thromboplastin time (PTT)

Partial thromboplastin time (PTT) is a blood test that looks at how long it takes for blood to clot. It can help tell if you have a bleeding problem or if your blood does not clot properly.

Platelet aggregation test

A platelet aggregation test checks how well your platelets clump together. The laboratory specialist will look at how the platelets spread out in the liquid part of the blood (plasma) and whether they form clumps after a certain chemical or drug is added. When platelets clump together, the blood sample is clearer. A machine measures the changes in cloudiness and prints a record of the results.

 

Prothrombin time (PT)

Prothrombin time (PT) is a blood test that measures the time it takes for the liquid portion (plasma) of your blood to clot. Prothrombin, also known as factor II, is just one of many plasma proteins involved in the clotting process. PT test may also be called an INR test. INR (international normalized ratio) stands for a way of standardizing the results of prothrombin time tests, no matter the testing method.

Treatment of bleeding disorder

Treatment depends on the type of disorder. It may include:

Clotting factor replacement

Fresh frozen plasma transfusion

 

Platelet transfusion

Medications

Oprelvekin

Oprelvekin is an interleukin, prescribed for severe thrombocytopenia caused by certain chemotherapy treatments.

Phylloquinone

Phylloquinone is often known as vitamin K1, prescribed for coagulation disorders (bleeding problems) in patients with vitamin K deficiency (e.g. Anticoagulant-induced prothrombin deficiency, hypoprothrombinemia). It helps the liver to produce blood-clotting factors.

Thrombin Topical Bovine Origin

Thrombin Topical Bovine Origin is hematologic agent, prescribed for hemostasis and for temporary control of moderately to severely bleeding wounds.

Tranexamic Acid

Tranexamic Acid is an antifibrinolytic agent, used for reduction or prevention of excessive menstrual bleeding. It is also used for prevention of bleeding due to other causes such as peptic ulcer, bypass surgery, prostatic surgery, and overdose of fibrinolytics.

Factor IX

Factor IX is a synthetic protein, clotting factor IX, prescribed for control and prevention of hemorrhagic episodes in patients with hemophilia B.

Fibrinogen Concentrate

Fibrinogen Concentrate is a hematological agent, prescribed for acute bleeding episodes in patients with congenital fibrinogen deficiency.

Goserelin

Goserelin is a synthetic analogue of gonadotropin-releasing hormone (GnRH) agonist, used to suppress production of the sex hormones (testosterone and estrogen), and prescribed for the treatment of endometriosis, breast and prostate cancer.

Aprotinin

This product is derived from bovine lung tissue, which inhibits certain enzymes that increase the risk for bleeding.

Carbazochrome

Carbazochrome is an antihemorrhagic agent, prescribed for bleeding disorders.

Antihemophiliac factor

Antihemophiliac factor is an essential blood-clotting factor, prescribed for controlling and preventing bleeding episodes in people with low levels of factor VIII (hemophilia A) and AHG deficiency. This product contains a man-made form of factor VIII, also called antihemophilic factor.

Prevention and control of bleeding disorder

This list tells you the minimum things to do.  You may want to do them more often or as your doctor suggests. Your hemophilia treatment center can help with these:

These are things you can do on your own

Exit mobile version